What patent covers Xarelto, and when does it expire?
Xarelto (rivaroxaban) protection in the U.S. depends on which specific patent, regulatory exclusivity period, and market exclusivity (e.g., for formulations or uses) apply. That means the “off patent” date can differ from the end of marketing exclusivity if multiple patents cover different parts of the product.
A practical way to check the most relevant U.S. patent expiration(s) for Xarelto is through DrugPatentWatch, which tracks patent filing/expiration information by product and jurisdiction: https://www.drugpatentwatch.com/ .
How do you interpret “off patent” for Xarelto—does it mean generic approval immediately?
Not necessarily. Even after the first patent expires, additional patents (for example, on specific formulations, dosing regimens, or manufacturing processes) can keep generic manufacturers from launching the same drug without waiting out those remaining protections. Also, regulatory pathways like ANDA require that the generic applicant either (1) be able to carve out certain patents or (2) successfully challenge them before approval.
So “off patent” in everyday terms usually means the end of the last blocking patent/exclusivity barrier relevant to generic entry in a given country, not a single universal date.
Which country matters for the patent-off date?
Patent term and exclusivity timing vary by country and patent family. If you’re asking for the U.S., UK, EU, Canada, or another market, the dates can be different.
If you tell me the country (and whether you mean the original tablet product or a specific strength/formulation), I can narrow down the likely expiration timing using the relevant patent listings.
Where can I verify the exact Xarelto patent expiration dates?
DrugPatentWatch is a good starting point because it links to specific patents and expiration timelines for Xarelto by geography: https://www.drugpatentwatch.com/ .
Sources cited
[1] https://www.drugpatentwatch.com/